Mutations in the developmental control gene PAX6 have been shown to be the genetic cause of aniridia, which is a severe panocular eye disease characterised by iris hypoplasia. The inheritance is autosomal dominant with high penetrance but variable expressivity. Here we describe a mutational analysis of 27 Danish patients using a dideoxy fingerprinting method, which identified PAX6 mutations in 18 individuals with aniridia. A thorough phenotype description was made for the 18 patients. A total of 19 mutations, of which 16 were novel, are described. Among these were five missense mutations which tended to be associated with a milder aniridia phenotype, and in fact one of them seemed to be non-penetrant. Four of the five missense mutations were located in the paired domain. We also describe a third alternative spliced PAX6 isoform in which two of the four missense mutations would be spliced out. Our observations support the concept of dosage effects of PAX6 mutations as well as presenting evidence for variable expressivity and gonadal mosaicism.
Introduction
Aniridia is a severe panocular disorder, with a reported incidence of 1 in 50 000 to 100 000. The disease is characterised by lack of iris development, often associated with cataracts, optic nerve hypoplasia and glaucoma. Severe age-related corneal degeneration is a frequent complication which contributes to a poor visual prognosis in aniridia. About one third of the cases are sporadic, and two thirds are familial, with an autosomal dominant inheritance, with high penetrance, but variable expressivity. 1 The sporadic cases can be part of the WAGR syndrome (Wilms' tumour, aniridia, genitourinary abnormalities and mental retardation) caused by a chromosomal deletion in the 11p13 region. 2 The human PAX6 gene was cloned in 1991 by positional cloning, 3 and has been isolated from both vertebrates and invertebrates including mouse, 4, 5 quail, 6 rat, 7 chicken, 8 zebrafish, 9, 10 Drosophila melanogaster, 11 sea urchin, 12 Caenorhabditis elegans, 13, 14 ribbonworm Lineus sanguineus, 15 ascidian Phallusia mammillata 16 and Xenopus laevis. 17 The human PAX6 gene spans 22 kb and consists of 14 exons. 18 The encoded protein contains two DNA binding domains, the paired box of 128 amino acids and a paired-type homeobox of 61 amino acids, separated by the linker region. The paired domain has two functional subdomains, the 74 amino acid N-terminal domain which is relatively conserved among paired domains, and the less well conserved 54 amino acid C-terminal domain. 19 PAX6 is alternatively spliced and inclusion of exon 5a (PAX6-5a) alters the DNA binding properties resulting in DNA contact by the C-terminal domain instead of the N-terminal domain. 19 Five different alternative spliced products have been identified in the bovine eye, 20 and several isoforms have also been reported in quail. 21 Furthermore, in the C-terminal part of the protein there is a proline, serine and threonine rich (PST) domain of 152 amino acids 3 which resembles the activation domain of transcription factors CTF-1 (CAAT-box binding transcription factor) 22 and Oct2, 23 and has been shown to possess transcriptional activity in vitro. 12, 24, 25 Quail Pax-6 has been shown to transactivate its own promoter, 26 and Pax-6 from mouse, chicken and guinea pig was shown to be involved in transcriptional regulation of crystallin genes. 27 Pax-6 belongs to the Pax family of developmental control factors 28 all possessing the paired domain originally identified in the Drosophila melanogaster segmentation gene paired. 29 A striking amino acid identity is observed of Pax-6 proteins between species, especially in the functional domains, with only one amino acid difference between the mouse and the human gene located in the alternatively spliced exon. 4, 18 The expression patterns of Pax-6 are also conserved throughout the vertebrates, 27 and transcripts have been detected in the developing eye, the brain and pancreas. 3 Based on findings in the small eye (Sey) mouse, 30 mutations in PAX6 were identified as the genetic cause of aniridia, and in the human PAX6 database there are reports of 118 mutations. 31, 32 Most of the mutations cause premature truncation of the protein, and only six missense mutations have been reported. Two of these are associated with classical aniridia, R208W 33 and I87R, 34 whilst the other four are associated with variable phenotypes; G18W caused congenital cataract (in the proband) and Peter's anomaly (in the mother) (PAX6 mutation database 31 ), R26G caused Peter's anomaly, 35 R128C caused foveal hypoplasia 36 and Q422R caused ocular anterior segment anomalies. 37 Yet another phenotype, autosomal dominant keratitis, has been associated with a splice site mutation (IVS10-2A > T) in PAX6. 38 Here, we report a mutational analysis of PAX6 in 27 Danish patients using dideoxy fingerprinting and DNA sequencing. 19 mutations were detected, including five new missense mutations, which tended to be associated with milder iris phenotypes.
Subjects and Methods

Patients
A total of 27 patients was investigated of whom 23 had aniridia, three had congenital cataract without aniridia, and one Peter's anomaly. The patients had no major chromosomal alterations or deletions in 11p13 as shown by conventional cytogenetic analysis (Q-banding), and FISH analysis using probes for PAX6 and WT1. A short summary of the phenotype is shown in Table 2 , and more detailed clinical case stories can be seen in the Appendix. Each patient was given a score from 1 to 6 based on the severity of the aniridia, with iris 1 being stromal hypoplasia with centrally located pupil, iris 2 stromal hypoplasia with eccentric pupil, iris 3 circumpupillary aplasia, iris 4 atypical sector coloboma ( < half circumference absent), iris 5 subtotal aniridia ( > half circumference absent) and iris 6 complete aniridia ( Figure 1 ).
The patient data were extracted from the medical files at the National Eye Clinic. Most patients were followed for several years and since some of the phenotypic characteristics (eg corneal dystrophy) are age-related, the birth years and the age at examination are indicated in the case reports. Observations from other eye departments and ophthalmologists in private practice were included in some cases.
DNA Extraction, PCR and Dideoxy Fingerprinting
Genomic DNA was isolated from blood leukocytes using standard salting out method. 39 Primers used in the study are shown in Table 1 . 18, 40 Annealing temperatures for the PCR amplification are shown in Table 1 , and the cycling profile was for all exons: an initial denaturation at 95°C for 5 min followed by 30 cycles of 95°C (30 s), annealing temperature (30 s), 72°C (30 s). A final extension step at 72°C for 7 min ended the protocol. Amplification was done in standard PCR buffer, using 0.011 units/µl AmpliTaq Gold polymerase from Perkin Elmer (California, USA) 50 µM of each dATP, dCTP, dGTP, dTTP and 0.4 µM of each primer.
For the mutation analysis, a sequencing reaction using one of the four dideoxy-nucleotides was performed for each exon (method modified from Sarker et al 1992 41 ). The sequencing product was analysed on a non-denaturing 0.5 ϫ MDE gel. Some of the exons were analysed twice with two different dideoxy nucleotides. If a shift in mobility was observed the PCR product was sequenced using the same primers as used for PCR and dideoxy fingerprinting.
Exon 13 was analysed by DNA sequencing using the 13F primer of the PCR product made by primers 13F and 13R. DNA sequencing was done using the cycle-sequencing kit from Amersham (Uppsala, Sweden) according to the manufacturer's instructions. All single nucleotide substitutions, except when located in splice sites, were confirmed by sequencing a second PCR product. normal controls, using the RNeasy mini kit from Qiagen (Hilden, Germany) following the manufacturer's instructions. The RNA (approximately 10 µg) was treated with 10 units DNaseI (Amplification grade from Gibco, Life Science (Maryland, USA)), following the manufacturer's instructions. 1 µg of total RNA was reverse transcribed using random hexamer primers and the SuperscriptII enzyme from Gibco (Life Science) following the manufacturer's instructions.
Nested RT-PCR was performed of two regions. Fragment 1 from nucleotide -51 to 962 and fragment 2 from nucleotide 1248 to 1622, nucleotide numbers according to Ton et al, 3 using the following primers listed.
Fragment 1 first PCR: forward primer: 1F: 5'-CAG AGG TCA GGC TTC GCT AA-3', reverse primer C130: 5'-CTT TCT CCA GGG CCT CAA T-3'. 33 Nested PCR: forward: 4F-N: 5'-GGT CAG GCT TCG CTA ATG GG-3' reverse primer C860: 5'-AGC CTC ATC TGA ATC TTC TCC-3'. Two µl cDNA was amplified in a 20 µl volume in standard PCR buffer, 250 µM of each dATP, dCTP, dGTP and dTTP, 0.5 µM of each primer, and 1.5 units AmpliqTaq Gold from Perkin Elmer. The DNA was initially denatured for 7 min at 95°C, followed by 35 cycles of denaturing at 95°C for 30 s, annealing at 55°C for 45 s and extension at 72°C for 3 min (1 min 30 s for fragment 2). The amplification was ended by a final extension at 72°C for 5 min. One µl of this PCR reaction was amplified using the nested primers in a 20 µl volume in standard PCR buffer, 125 µM of each dATP, dCTP, dGTP and dTTP, 0.5 µM of each primer and 1 unit of AmpliTaq Gold. The DNA was denatured initially for 7 min at 95°C, followed by 35 cycles of amplification with denaturing at 95°C for 30 s, annealing for 45 s at 55°C and extension at 72°C for 2 min and a final extension at 72°C for 5 min. The products were visualised on ethidium bromide stained agarose gels.
Identification of PAX6 Isoforms in Human Brain cDNA by RT-PCR
Primers 1F and C130 (see above) were used for the initial PCR as described using 2 ng human brain, cerebellum Quickclone cDNA from Clontech (California, USA). 0.5 µl of this PCR product was amplified using nested primers: C127: 
Results
Mutational analysis of PAX6 by dideoxy fingerprinting and DNA sequencing revealed mutations in 18 patients ( Figure 2 and Table 2 ). A total of 19 mutations were found, of which 16 are novel. We also found an already known polymorphism in intron 9 in two patients, 42 and a silent mutation in exon 10.
Twelve mutations were single nucleotide substitutions of which six were missense mutations, three were nonsense mutations and the remaining three were located in introns, and would be expected to cause splice errors. Two of the nonsense mutations were identical. Six of the mutations were deletions or insertions that were predicted to cause frameshifts, and finally we found a 4 bp deletion in the 5' untranslated region (5'UTR) in exon 3. In the patients in whom we did not observe any shifts in band mobility in the dideoxy fingerprinting analysis, we performed DNA sequencing of selected exons (exon 4 (in all but one), 5, 6, 7 (in three patients), 8, 10, 11 and 12 (in all but one)). With this strategy we identified one additional mutation (in case 29).
We did not detect mutations in PAX6 in the three patients with congenital cataract, in the patient with Peter's anomaly, nor in five patients with aniridia.
Missense and Nonsense Mutations
In case 4 we found two missense mutations, one in exon 6 in the paired domain (598C > A) changing alanine 79 to glutamic acid (A79E), and the second in exon 8 in the linker region (985G > A) changing codon 208 from arginine to glutamine (R208Q). Sequencing of the parents' PAX6 genes showed that the unaffected mother carried the R208Q mutation, whilst the affected father possessed the A79E mutation. Care was taken to assure that no sample switch had taken place, by repeating the sequencing, and by checking that samples were XX and XY respectively, using PCR amplification of the amelogenin gene (data not shown). Two affected 18 except (a) which we designed outselves and (b) which were HP6-11up and HP6-12down from Maas et al.
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PAX6 mutations K Grønskov et al t siblings had both mutations like the index patient. The alanine 79 residue has been conserved in all investigated PAX6 genes. However, in a comparison of the paired domains from 14 representative Pax genes (PAX1, PAX2, PAX3, Pax-4, PAX5, PAX6, PAX7, PAX8, PAX9, prd, Gsbn, Gsb, Poxmeso, Poxn) alanine 79 is conserved in nine of them, whilst it is replaced with an threonine in the remaining five; it has not been found to make DNA contact. 43 The arginine 208 has been conserved in all cloned PAX6 genes.
Another missense mutation was found in case 5 in exon 6 in the paired domain (519G > C) changing valine 53 to leucine (V53L). This valine is conserved in all investigated PAX6 genes, and also in the 14 representative paired domains; it does not seem to make DNA contact. 43 Family studies showed that the affected mother possessed the mutation, whilst the healthy father did not.
In case 13 a 487T > G substitution was found in the paired domain in exon 5 changing isoleucine 42 to serine (I42S). This isoleucine has been conserved in all investigated PAX6 genes and also in the 14 abovementioned paired domains, but it does not seem to make DNA contact. 43 In this family it was not possible to make segregation analysis.
In case 16 we found a mutation in exon 4 of the start codon changing the ATG codon for methionine to AAG which is the codon for lysine (M1K).
Finally, in case 23 a missense mutation was found in exon 6 in the paired domain changing threonine 63 to proline (T63P) due to a 549A > C substitution. This residue is also conserved both in all PAX6 genes and in the 14 paired domains but has not been found to make DNA contact. 43 We did not have the opportunity to investigate this family further.
Cases 22 and 34 possessed the same nonsense mutation R317X (1311C > T), which has previously been identified in four other non-related patients. 31, 42, 44, 45 We also found a novel nonsense mutation in the homeobox domain in case 32 changing codon 261 CGA for arginine to the stopcodon TGA (R261X) (1143C > T).
Splice Mutations
The dideoxy fingerprinting displayed three nucleotide substitutions located in splice sites, which would be predicted to cause splice errors.
We found a substitution in the 5' splice site of intron 3 (IVS3 + 1G > A) in case 18. RT-PCR analysis of fragment 1 showed a deviating 700 bp fragment in addition to three larger fragments also observed in controls ( Figure 3A) . The larger fragments correspond to alternatively spliced forms of PAX6 (see below). 18, 20 The smaller fragment was excised from the gel and left in H 2 O overnight and subjected to DNA sequencing using the same primers as for the nested PCR. This showed skipping of exons 3, 4, 5 and 5a. Since exon 4 contains the translation start site no protein synthesis would be expected from this allele.
Another splice mutation was found in the 5' splice site of intron 11 (IVS11 + 1G > A) in case 35. RT-PCR analysis of fragment 4 showed amplification of two Figure 3B ). The fragments were excised from the gel and eluted in H 2 O overnight and sequenced. This showed that the smaller fragment lacked exon 11. This would lead to premature termination of the protein after incorporation of 25 erroneous amino acids. In case 30 a previously reported substitution in intron 6 was found (IVS6 + 1G > A). 33, 42 We did not have EBV transformed lymphocytes from this patient and therefore it was not possible to do RT-PCR analysis. However, the mutation has been reported to cause usage of a cryptic splice site in exon 6.
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Insertions and Deletions
Case 3 had a substitution and a deletion in exon 12, substituting 1520G and 1521G with a single T (1520GG > T). This would lead to a frameshift, and an aberrant and extended protein from codon 386.
Another patient (case 17) had a deletion of 598C and 599G with an insertion of TTTGCTTACA following nucleotide 597 in exon 6 in the paired domain (598delCG, 597ins10), which would introduce a stop codon after incorporation of eight aberrant amino acids. The 10 nucleotides are identical to the inverted sequence from nucleotide 611 to 620. The patient's brother also had aniridia, and upon sequencing he was found to have the same insertion as the patient, whereas the mutation could not be found in DNA extracted from whole blood from the healthy parents. This family most likely represents gonadal mosaicism in one of the parents.
Case 15 had a complex substitution of 495A by CAT (495A > CAT), leading to a frameshift and introduction of a stopcodon in exon 6 after incorporation of 9 erroneous amino acids. Furthermore, we found a silent mutation in exon 10 in this patient substituting 1193G with an A.
A one base pair deletion was found in case 21 in exon 7 in the linker region (853delC). This would lead to a frameshift and premature termination in exon 8 preceded by 42 erroneous amino acids.
In case 27 we found a 14 base pair insertion in exon 6 where nucleotides 705-718, both included, were duplicated and inserted between nucleotide 718 and 719 (718ins14). This would lead to premature termination after incorporation of nine incorrect amino acids.
In case 29 we found a one base pair deletion (764delG), in exon 7 in the linker region. The mutation would cause a frameshift and premature termination after incorporation of 12 erroneous amino acids.
We also found a four base pair deletion in exon 3 (246del4) located before translation start site in case 31. It is difficult to say if this would have any effect on transcription or translation. It was not possible to do segregation analysis in this family.
PAX6 Isoforms
RT-PCR analysis of illegitimate transcripts from lymphoblastoid cells from patients and controls showed several fragments. To verify the expression pattern we studied a sample of human brain cDNA and found the same isoforms (Figure 4) . Primers 1F and C130 were used for the initial PCR and the nested primers used are shown in Figure 4A . Amplification with C127 and C860 showed four fragments of approximately 450 bp, 560 bp, 610 bp and 650 bp, which were sequenced ( Figure 4B ). The 650 bp and 610 bp bands represented the PAX6-5a and the canonical PAX6 isoforms respectively. The 450 bp fragment represented the PAX6-5a,6' isoform containing exon 5a, but using an alternative 5' splice site in exon 6, thereby including only 15 bp of exon 6. The alternative 5' splice site in exon 6 was previously reported for bovine eye 20 and quail, 21 but to our knowledge not in humans. Attempts to sequence the 560 bp fragment failed, furthermore this fragment was not amplified regularly, and it could represent mispriming. This was also the case for the 430 bp fragment amplified with primers C141 and C860. PCR amplification with various primer combinations showed the expected fragment sizes ( Figure 4B ).
Discussion
Mutations in the paired box gene PAX6 have been recognised as the genetic cause of aniridia. Pax-6 has been extremely well conserved through evolution, and both the mouse Pax-6 gene and the ascidian Phallusia mammillata Pax-6 gene were able to induce eye formation in Drosophila. 16, 46 It is assumed that aniridia arises from haploinsufficiency based on the phenotypical resemblance of individuals deleted for one copy of the gene and intragenic mutations.
We identified mutations in 18 of 23 aniridia patients. No mutations were found in three congenital cataracts and one Peter's anomaly patients.
The reason we did not detect mutations in all aniridia patients could be methodological, ie the sensitivity of the dideoxy fingerprinting method. Another possibility is that the mutations are located outside the examined region, for example in the promoter region or in intron sequences distant from the splice sites. Furthermore, it has been shown that alterations in sequences distant from the PAX6 gene can cause aniridia, as seen from two translocation patients described by Fantes et al, 47 where the translocation breakpoint was located at least 85 kb from the PAX6 gene. Phenocopy or other genetic causes could be a possibility especially in congenital cataract and Peter's anomaly.
Eleven of the described mutations were predicted to cause premature truncation of PAX6 (cases 15, 17, 21, 22, 27, 29, 32, 34 and 35) or to abolish translation (cases 16 and 30), and were expected to give a severe phenotype. Indeed nine of them scored iris 5 or 6. The mutation found in case 3 would be expected to result in translation beyond the normal stop codon. The phenotype was moderately mild (iris 3), and possibly the PAX6 protein retains some of its activity. An extended PAX6 protein has been reported previously in a familial case of aniridia. 33 An interesting case was 31 where we found a 4 base pair deletion in exon 3 upstream of the ATG initiation codon. This is the first variation found in exon 3 to our knowledge. However, since we did not have the opportunity to analyse family members, we cannot be sure that this mutation is the disease-causing factor, or a polymorphism.
A striking question has been why so few missense mutations have been identified so far in the PAX6 gene. Among the 118 mutations reported in the PAX6 mutation database, 31 only six are missense mutations, of which four were reported to have a deviant (nonaniridia) phenotype, whilst there are around 70 other single base pair substitutions reported. A PAX6 protein with an amino acid substitution could still retain some residual activity depending on the type and position of It has been shown in the bovine eye that the 5a isoform predominates in the iris in contrast to the lens and retina where PAX6 and PAX6-5a seem to be equally represented, 20 indicating that the PAX6-5a isoform is important for iris development. This is interesting since four of our missense mutations are located outside the helices in the C-terminal subdomain thought to make DNA contact in PAX6-5a, and these patients all show a mild iris phenotype, whereas the lenses were affected. Furthermore, we identified a third PAX6 isoform PAX6-5a,6' in human cerebellum (Figure 4) also present in lymphoblastoid cells, in which two of the four missense mutations would be spliced out and consequently not affect the function of this isoform. A third missense mutation was located in the alternative 5' splice site in exon 6, and consequently would result in absence of the PAX6-5a,6' isoform. These results support the hypothesis that missense mutations in PAX6 could cause deviant phenotypes. One patient with a missense mutation was ranked as an iris 6 (case 16, M1K). However, this must be considered a null allele, since the mutation disrupts the initiation codon (ATG changed to AAG), and this has been shown from other genes to abolish translation. [48] [49] [50] Aniridia has always been considered to be fully penetrant, but with great variation in expressivity. In the present investigation we present evidence for a non-penetrant mutation, a mutation with variable expressivity, as well as gonadal mosaicism. The nonpenetrant PAX6 mutation (R208Q) was found in the healthy mother of case 4 who was a compound heterozygote for two missense mutations. That the R208Q mutation is non-penetrant is unexpected, because of the extreme conservation of the PAX6 gene through evolution. Moreover, arginine 208 has been found mutated to a tryptophan (R208W) in an affected female and her affected son. 33 It could be argued, however, that a change to glutamine is less radical than a change to tryptophan based on the resemblance of the side chains. Indeed, if both missense mutations caused nonfunctional PAX6 proteins, a more severe phenotype of case 4 and her siblings would be expected, 24 in fact case 4 displays a very mild phenotype. This is also an argument against the possibility of the mother having the mutation in a mosaic form.
Arginine 208 is part of four amino acid motif (LKRK) located just upstream of the homeodomain which was thought to be conserved in all PAX genes with an intact homeodomain. However, recently the cloning of PAX4 showed that the motif is not conserved in this gene. 51 In vitro experiments using transfected COS7 cells showed that the R208W mutation prevented nuclear localisation of PAX6, 52 whilst similar experiments in quail showed normal nuclear localisation, 53 leaving some uncertainty of the biological consequences of the R208W mutation.
Gonadal mosaicism was probably the explanation for the transmission in the family of case 17 in whom a deletion and insertion event had taken place (598delCG, 597ins10). The same mutation was present in an affected brother but not in the parents. Microsatellite analysis with four polymorphic markers (WT1, D11S929, D11S2071 and TH, data not shown) showed no contradiction of the parents being the biological parents of the two children.
This paper confirms the phenomenon of variable expressivity, since we found two patients with the same nonsense mutation (R317X), but whereas one patient scored iris 6, the other showed a notably milder phenotype and was classified as iris 3. The patient with the milder phenotype was a sporadic case, and mosaicism could be considered as a possible explanation. However, variable phenotypes within a family have been described, 54 indicating that other factors than the mutated PAX6 protein contributes to phenotype. Some stochastic variation in expression must exist and a disease caused by haploinsufficiency could be expected to be very sensitive to such fluctuations.
In conclusion, our investigation of a large number of clinically well characterised aniridia patients showed a relatively large percentage with missense mutations, associated especially with mild phenotypes, but early cataract. This further strengthens the concept of a dosage effect of PAX6 mutations.
Variable expressivity and apparently non-penetrance were also observed, indicating that other factors than PAX6 mutations may influence the phenotype. Pronounced horizontal nystagmus, total aniridia, transparent small corneas measuring 8.5-9 mm horizontally, and cataracts with zonular and posterior cortical opacities were present during her childhood. Cataract discission was performed when she was 18 years old. Goniscopy revealed rudimentary iris remnants and whitish fibrous material in the anterior chamber angle and at 28 years of age she developed glaucoma. Only mild photophobia was present. Visual acuity on both eyes was 0.1 in 1965 and improved after cataract surgery to 0.25 + 12.00 sph. Nystagmus and aniridia were diagnosed shortly after birth. Close ophthalmological control since the age of 6 months. At the initial examination complete aniridia and dense zonular cataracts were found. Gonioscopy revealed small iris remnants, open anterior chamber angles with membranaceous tissue strands. Complicating glaucoma was diagnosed before 1 year of age. At 10 years her visual acuity was 0.1 on both eyes. At age 35 the visual acuity had dropped to 0.01, and at the last Nystagmus and total aniridia were observed soon after birth. Later, lens dislocation, lens coloboma, and posterior corneal and zonular cataracts were noticed. Glaucoma was diagnosed at the age of 8 years and was treated intensely by medication and surgically. Despite treatment, visual acuity deteriorated and in 1972 a blind, painful right eye was enucleated. Histopathological examination revealed rudimental iris tissue which adhered to a fibrous trabecular meshwork. The optic nerve head was deeply excavated. The cornea seemed to lack Bowman's membrane and a few peripheral vessels were present in the peripheral part of the corneal stroma. Later on, her left eye developed marginal corneal vascularisation and opacification. In 1962 the visual acuity was 0.1 on both eyes. In 1997 the visual acuity of the left eye was 0.01 and her visual field was restricted to the 20° isopter. Sickle-shaped iris remnants were located upwardnasally. Nystagmus, conspicuous marginal corneal dystrophy, slight posteriorly situated opacities in both crystalline lenses, and foveal hypoplasia were observed. Visual acuity (1953) right eye: 0.2 with + 2.0 sph., left eye: 0.25 with + 3.0 sph.
